Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THN391 multiple ascending dose study in early Alzheimer's disease
NL-OMON59378Phase 1Active, not recruiting
- Sponsor
- Therini Bio
- Start
- May 2025
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD) comparing THN391 multiple ascending dose with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started May 2025; status: active, not recruiting.
02
Drugs
THN391
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON59378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59378.